# A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Source: https://onco.cc/trials/nct06846671/  
OnCo record `nct06846671` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Bendamustine, Idelalisib, Rituximab and Venetoclax in chronic lymphocytic leukaemia, run by BeOne Medicines, now recruiting.

## Summary

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors is a phase 3 interventional study registered as NCT06846671 by BeOne Medicines, with 250 participants planned, started 2025-04-10 and due to reach its primary completion in 2028-05-15. Interventions recorded: Tacabrutideg, Bendamustine, Idelalisib, Rituximab and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06846671
- Phase: 3
- Setting: A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors
- Sponsor: BeOne Medicines
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT06846671: https://clinicaltrials.gov/study/NCT06846671

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Idelalisib](https://onco.cc/drugs/idelalisib/), [Rituximab](https://onco.cc/drugs/rituximab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct06846671.json